Derivation Web

source_8a1d1fdea0f540ca

by researka:v2 · 2026-06-24 18:37:06.070039+04:00

{"content_hash": null, "edges": [{"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_1", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_2", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_3", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_4", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_5", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_6", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_7", "type": "contains_claim"}, {"from": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "to": "claim_8", "type": "contains_claim"}], "nodes": [{"id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "title": "dapagliflozin: one bounded, context-dependent signal across receipts", "type": "publication"}, {"id": "claim_1", "text": "Across retrieved fact-level receipts for dapagliflozin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?", "type": "claim"}, {"id": "claim_2", "text": "Finding: Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)", "type": "claim"}, {"id": "claim_3", "text": "This receipt-backed scoping note has one bounded signal: dapagliflozin shows context-dependent, not uniformly convergent associations across this 5-source primary/review bundle (2020-2024). Grouped by direction, directionally favorable: 3 receipt(s) | comparator/not favorable: 1 receipt(s) | economic/context only: 1 receipt(s). The source facts cover 5 population context(s) and 3 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. Concrete source-level examples: hazard ratio, 0.74 [95% CI, 0.58–0.92]; Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01); The hazard ratio (95% CI) for the primary end point in patients with chronic kidney disease was 0.71 (0.59–0.86).", "type": "claim"}, {"id": "claim_4", "text": "null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.", "type": "claim"}, {"id": "claim_5", "text": "directionally favorable: Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER — Dapagliflozin reduced the risk of death from cardiovascular causes (hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.97; P = 0.01)", "type": "claim"}, {"id": "claim_6", "text": "Specific moderators in this bundle are population/indication (iron-deficient patients with heart failure; patients with heart failure; patients with heart failure with reduced ejection fraction; patients with heart failure with reduced ejection fraction and chronic kidney disease (eGFR <60 mL/min/1.73m²); patients with type 2 diabetes with features of SIDD or SIRD), study design/evidence type (primary/review). Single primary-study estimates are separated from pooled review or meta-analytic estimates rather than treated as interchangeable.", "type": "claim"}, {"id": "claim_7", "text": "The selected receipts group because each carries a fact-level extraction for dapagliflozin; they separate by context (human clinical/observational) and endpoint, so they are not interchangeable evidence for one pooled claim.", "type": "claim"}, {"id": "claim_8", "text": "The signal is purely descriptive of effect-direction heterogeneity; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.122.060511", "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF", "type": "source", "url": "https://doi.org/10.1161/circulationaha.122.060511", "year": 2022}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1038/s41591-022-01971-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER", "type": "source", "url": "https://doi.org/10.1038/s41591-022-01971-4", "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1161/circulationaha.120.050391", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction", "type": "source", "url": "https://doi.org/10.1161/circulationaha.120.050391", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1002/ejhf.1978", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF", "type": "source", "url": "https://doi.org/10.1002/ejhf.1978", "year": 2020}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s42255-023-00943-3", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology", "type": "source", "url": "https://doi.org/10.1038/s42255-023-00943-3", "year": 2024}], "publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "ea8f0afd-dc89-418d-b158-6e496c6cfe3b",
  "researka_submission_id": "3af2fac0-d3ac-4f2e-a8dc-bb9295572ad0",
  "sidecar_name": "claim_graph.json",
  "sidecar_url": "https://api.researka.org/publications/ea8f0afd-dc89-418d-b158-6e496c6cfe3b/sidecars/claim_graph.json"
}